Seattle Genetics to Present at Upcoming Investor Conferences

BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (NASDAQ: SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from the Seattle Genetics website at www.seattlegenetics.com in the Investors and News section.

Bank of America Merrill Lynch 2016 Health Care ConferenceWednesday, May 11, 11:20 a.m. Pacific Time, Las Vegas

UBS Global Healthcare ConferenceTuesday, May 24, 10:30 a.m. Eastern Time, New York

About Seattle Genetics

Seattle Genetics is an innovative biotechnology company that develops and commercializes novel antibody-based therapies for the treatment of cancer. The company’s industry-leading antibody-drug conjugate (ADC) technology harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. ADCETRIS® (brentuximab vedotin), the company’s lead product, in collaboration with Takeda Pharmaceutical Company Limited, is the first in a new class of ADCs approved globally in more than 60 countries for relapsed classical Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL). Seattle Genetics is also advancing vadastuximab talirine (SGN-CD33A; 33A), an ADC that is expected to move into a phase 3 trial for acute myeloid leukemia in 2016. Headquartered in Bothell, Washington, Seattle Genetics is also advancing a robust pipeline of innovative therapies for blood-related cancers and solid tumors designed to address significant unmet medical needs and improve treatment outcomes for patients. The company has collaborations for its proprietary ADC technology with a number of companies including AbbVie, Astellas, Bayer, Genentech, GlaxoSmithKline and Pfizer. More information can be found at www.seattlegenetics.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20160504005506/en/

Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
[email protected]

Source: Seattle Genetics, Inc.

You May Also Be Interested In

• BofA Securities Downgrades Bending Spoons (BSP) to Underperform
• North Dakota's largest treasure hunt for $25,000 launches Aug. 21
• Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update